Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Articles by Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Latest Updated Articles
Management of Adverse Effects in R/R HER2+ mBCPublished: September 23rd 2020 | Updated:
FDA-approved Therapies for Relapsed/Refractory HER2+ mBCPublished: September 23rd 2020 | Updated:
Practical Management of Early Stage HER2+ Breast CancerPublished: September 23rd 2020 | Updated:
HER2-targeted Therapy: Routes of AdministrationPublished: September 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5